{
  "source": "PA-Notification-Gattex.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1035-12\nProgram Prior Authorization/Notification\nMedication Gattex® (teduglutide [rDNA origin]), for injection, for subcutaneous use\nP&T Approval Date 2/2013, 11/2013, 11/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019,\n9/2020, 9/2021, 9/2022, 9/2023, 9/2024\nEffective Date 12/1/2024\n1. Background:\nGattex® (teduglutide) is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of\nadults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are\ndependent on parenteral support.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Gattex will be approved based upon both of the following criteria:\na. Diagnosis of Short Bowel Syndrome (SBS)\n-AND-\nb. Dependent on parenteral support\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Gattex will be approved based on the following criterion:\na. Documentation of positive clinical response to Gattex therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Gattex [package insert]. Lexington, MA: Takeda Pharmaceuticals, Inc.; February 2024.\nProgram Prior Authorization/Notification - Gattex (teduglutide [rDNA origin])\nNotification\nChange Control\n2/2013 New criteria.\n11/2013 Formatting update. Removal of dose information in Background\nSection.\n11",
    " Prior Authorization/Notification - Gattex (teduglutide [rDNA origin])\nNotification\nChange Control\n2/2013 New criteria.\n11/2013 Formatting update. Removal of dose information in Background\nSection.\n11/2014 Annual review. Increased reauthorization approval duration to 60\nmonths.\n11/2015 Annual review. Revised initial authorization criteria to remove 12\nconsecutive months of PN/IV support therapy.\n9/2016 Annual review. Reduced reauthorization approval duration to 24\nmonths. Updated reference.\n9/2017 Annual review. No changes.\n9/2018 Annual review. No changes.\n9/2019 Annual review. Updated background and references. No changes to\ncriteria.\n9/2020 Annual review. No changes to criteria.\n9/2021 Annual review with no changes to criteria. Updated references.\n9/2022 Annual review. Added state mandate footnote. Updated\nreauthorization duration to the standard 12 months.\n9/2023 Annual review with no changes to criteria. Updated reference.\n9/2024 Annual review. Updated initial authorization duration to 12 months.\nUpdated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}